Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

265005 Dexamethasone - CAS 50-02-2 - Calbiochem

265005
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

Empirical FormulaCAS #
C₂₂H₂₉FO₅ 50-02-2

Products

Número de referenciaEmbalaje Cant./Env.
265005-100MG Ampolla de plást. 100 mg
Description
OverviewMost active and highly stable glucocorticoid. Causes a reduction in cyclin A and Cdk2 activity, and inhibition of G1/S transition in osteoblasts. Inhibits the phosphorylation of retinoblastoma (Rb) protein. Inhibits the expression of inducible but not constitutive nitric oxide synthase in vascular endothelial cells (IC50 = 5 nM). Enhances active cation transport in aortic smooth muscle cells by stimulating the Na+ - K+ pump. Induces apoptosis in human thymocytes.
Catalogue Number265005
Brand Family Calbiochem®
Synonyms9α-Fluoro-16α-methylprednisolone
References
ReferencesReil, T.D., et al. 2000. J. Surg. Res. 92, 108.
Smith, E., et al. 2000. J. Biol. Chem. 275, 1992.
Petit, P.X., et al. 1995. J. Cell Biol. 130, 157.
Stern, N., et al. 1994. Am. J. Hypertens. 7, 146.
Donis, J.A., et al. 1993. Biotechniques 15, 786.
Ohoka, Y., et al. 1993. Biochem. Biophys. Res. Commun. 197, 916.
Sarin, A., et al. 1993. J. Exp. Med. 178, 1693.
Vandewalle, A., et al. 1993. J. Cell Physiol. 156, 383.
Nieto, M.A., et al. 1992. Clin. Exp. Immunol. 88, 341.
Walsh, D., and Avashia, J. 1992. Cleveland Clin. J. Med. 59, 505.
Warters, R.L. 1992. Cancer Res. 52, 883.
Sperber, K., et al. 1991. J. Allergy Clin. Immunol. 87, 490.
Radomski, M.W., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 10043.
Bettger, W.J., et al. 1981. Proc. Natl. Acad. Sci. USA 78, 5588.
Product Information
CAS number50-02-2
ATP CompetitiveN
FormWhite solid
Hill FormulaC₂₂H₂₉FO₅
Chemical formulaC₂₂H₂₉FO₅
ReversibleN
Structure formula ImageStructure formula Image
Applications
ApplicationDexamethasone, CAS 50-02-2, is one of the most active and highly stable glucocorticoids. Inhibits the expression of inducible, but not constitutive NOS in vascular endothelial cells (IC50 = 5 nM).
Biological Information
Primary TargetPhosphorylation of rb protein
Primary Target IC<sub>50</sub>5 nM Inhibiting the expression of inducible but not constitutive nitric oxide synthase in vascular endothelial cells
Purity≥99% by TLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSTU3980000
Safety Information
R PhraseR: 36/37/38-43-63

Irritating to eyes, respiratory system and skin.
May cause sensitization by skin contact.
Possible risk of harm to the unborn child.
S PhraseS: 24-26-36/37

Avoid contact with skin.
In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Wear suitable protective clothing and gloves.
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Carcinogenic / Teratogenic
Storage +2°C to +8°C
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications

Documentation

Dexamethasone - CAS 50-02-2 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Dexamethasone - CAS 50-02-2 - Calbiochem Certificados de análisis

CargoNúmero de lote
265005

Referencias bibliográficas

Visión general referencias
Reil, T.D., et al. 2000. J. Surg. Res. 92, 108.
Smith, E., et al. 2000. J. Biol. Chem. 275, 1992.
Petit, P.X., et al. 1995. J. Cell Biol. 130, 157.
Stern, N., et al. 1994. Am. J. Hypertens. 7, 146.
Donis, J.A., et al. 1993. Biotechniques 15, 786.
Ohoka, Y., et al. 1993. Biochem. Biophys. Res. Commun. 197, 916.
Sarin, A., et al. 1993. J. Exp. Med. 178, 1693.
Vandewalle, A., et al. 1993. J. Cell Physiol. 156, 383.
Nieto, M.A., et al. 1992. Clin. Exp. Immunol. 88, 341.
Walsh, D., and Avashia, J. 1992. Cleveland Clin. J. Med. 59, 505.
Warters, R.L. 1992. Cancer Res. 52, 883.
Sperber, K., et al. 1991. J. Allergy Clin. Immunol. 87, 490.
Radomski, M.W., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 10043.
Bettger, W.J., et al. 1981. Proc. Natl. Acad. Sci. USA 78, 5588.

Folleto

Cargo
Tools and Tips for Analyzing Apoptosis
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision21-November-2008 RFH
Synonyms9α-Fluoro-16α-methylprednisolone
DescriptionMost active and highly stable glucocorticoid. Inhibits the expression of inducible but not constitutive nitric oxide synthase in vascular endothelial cells (IC50 = 5 nM). Enhances active cation transport in aortic smooth muscle cells by stimulating the Na+-K+ pump. Has anti-inflammatory and antirheumatic properties. Induces apoptosis in human thymocytes. In general, 500-1000 nM of dexamethasone is sufficient to induce apoptosis following a 6 h incubation at 37°C.
FormWhite solid
CAS number50-02-2
RTECSTU3980000
Chemical formulaC₂₂H₂₉FO₅
Structure formulaStructure formula
Purity≥99% by TLC
SolubilityDMSO (25 mg/ml), chloroform or Ethanol
Storage +2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
Toxicity Carcinogenic / Teratogenic
Merck USA index14, 2943
ReferencesReil, T.D., et al. 2000. J. Surg. Res. 92, 108.
Smith, E., et al. 2000. J. Biol. Chem. 275, 1992.
Petit, P.X., et al. 1995. J. Cell Biol. 130, 157.
Stern, N., et al. 1994. Am. J. Hypertens. 7, 146.
Donis, J.A., et al. 1993. Biotechniques 15, 786.
Ohoka, Y., et al. 1993. Biochem. Biophys. Res. Commun. 197, 916.
Sarin, A., et al. 1993. J. Exp. Med. 178, 1693.
Vandewalle, A., et al. 1993. J. Cell Physiol. 156, 383.
Nieto, M.A., et al. 1992. Clin. Exp. Immunol. 88, 341.
Walsh, D., and Avashia, J. 1992. Cleveland Clin. J. Med. 59, 505.
Warters, R.L. 1992. Cancer Res. 52, 883.
Sperber, K., et al. 1991. J. Allergy Clin. Immunol. 87, 490.
Radomski, M.W., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 10043.
Bettger, W.J., et al. 1981. Proc. Natl. Acad. Sci. USA 78, 5588.